MVP and AES

  • Number of citations of the paper that reports this interaction (PMID 24722188)
  • 1
  • Data Source:
  • BioGRID (two hybrid)

MVP

AES

Gene Name major vault protein amino-terminal enhancer of split
Image No pdb structure
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
Protein-Protein Interactions 57 interactors: ADAMTSL4 AES BANP BZRAP1 C1orf94 CALCOCO2 CAMK2B CCDC36 CKAP4 CYTB DISC1 DLX2 EPHX2 ESR1 FAM154A FAM46C GIT2 GOLGA2 HP KCTD9 KPNA2 KPNA3 MDFI MEOX1 MEOX2 MID2 MKL1 NNT NOTCH2NL OBFC1 PARP4 PIH1D2 PLSCR1 POT1 PSTPIP1 PTEN PTPN11 RAB3IP RBPMS REL RHOXF2 RIMBP3 RNF111 SERTAD1 SKIL SLC2A4 TCF4 TFCP2 TP53 TRAF2 TRIM27 TRIM42 TRIP13 TRIP6 VAC14 ZBTB32 ZMIZ2 138 interactors: ABI2 AEN AR ARHGAP32 ATN1 BAHD1 BCL6 BHLHE40 BIRC7 BYSL C1orf109 C1orf216 C1orf94 C6orf165 CALCOCO2 CAPN1 CARD9 CCDC57 CCL7 CCNJL CCNK CIB3 CPSF7 CRACR2A CRX CTAGE5 DDX6 DGCR6 DIP2A EAF1 EIF4E2 FAM124A FAM124B FBF1 FOXP2 FRS3 FSD2 GABARAP GFAP GFI1B GOLGA2 GORASP2 GRB2 GTF2E1 HMGB1 HNF1A HNRNPF HOMEZ IKZF3 KANK2 KIFC3 KRT13 KRT15 KRT31 KRT40 KRTAP10-3 KRTAP10-7 KRTAP10-8 KRTAP10-9 L3MBTL2 LDOC1 LINC00526 LMO1 LMO2 LMO4 LSM2 MAGOHB MAPK14 MBNL1 MED31 MED4 MFAP1 MLX MORF4L2 MSX1 MTUS2 MVP MYO15B NAB2 NCDN NEK6 NOTCH2NL NUDT22 OLIG3 OSGIN1 PARVG POU2F1 PPP1R16A PRDM1 PRKAA1 PRKAA2 PRPF31 PRR3 PTRH2 QARS RBM10 RBPMS REL RELA RFX6 RHOXF2 RIMBP3 RNF31 RPL18A RUNX1 SCNM1 SDCBP SH3GL3 SIX1 SIX2 SIX3 SIX6 SKIL SMAD3 SNCAIP SNRPC SOX5 SRPK2 STK16 STX11 TBX3 TCF4 TMCC2 TRAF1 TRAF2 TRIM26 TRIM27 TRIM41 TSC22D4 TSGA10 TSSK3 U2AF2 UBXN11 VPS37B VPS37C ZBTB24 ZGPAT ZNF576
Entrez ID 9961 166
HPRD ID 05475 02556
Ensembl ID ENSG00000013364 ENSG00000104964
Uniprot IDs B4DP93 Q14764 Q08117 Q8WY48
PDB IDs 1Y7X
Enriched GO Terms of Interacting Partners?
Tagcloud ?
afp  bleomycin  bronchogenic  cap  chance  cisplatin  cooperative  crs  cyclophosphamide  doxorubicin  eastern  ecog  efficacious  entered  est  evaluable  fluorouracil  institution  lethal  mitomycin  modest  nscbc  october  oncology  prs  regimens  shrinkage  threatening  vinblastine 
auger  bonefit  branemark  depths  differently  friatec  germany  goteborg  implants  imz  mannheim  nobelpharma  osseointegrated  osseointegration  outermost  peaks  photoelectron  pure  shifted  spectroscopy  speculated  spray  straumann  sweden  switzerland  tio2  titanium  waldenburg  xps 
Tagcloud (Difference) ?
afp  bleomycin  bronchogenic  cap  chance  cisplatin  cooperative  crs  cyclophosphamide  doxorubicin  eastern  ecog  efficacious  entered  est  evaluable  fluorouracil  institution  lethal  mitomycin  modest  nscbc  october  oncology  prs  regimens  shrinkage  threatening  vinblastine 
auger  bonefit  branemark  depths  differently  friatec  germany  goteborg  implants  imz  mannheim  nobelpharma  osseointegrated  osseointegration  outermost  peaks  photoelectron  pure  shifted  spectroscopy  speculated  spray  straumann  sweden  switzerland  tio2  titanium  waldenburg  xps 
Tagcloud (Intersection) ?